Announcements Trials
Browse Landscape

Phase

Phase 2 82Phase 1 42Phase 1/2 41Phase 3 27Phase NA 5Phase 4 5Phase 2/3 2Phase EARLY_PHASE1 1

Status

Completed 5Active not recruiting 3Withdrawn 2Recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 6pembrolizumab 5Radiosurgery 5Nivolumab 4Fluorouracil 4Carboplatin 4Blood Specimen Collection 4Biopsy 4X-Rays 3Vincristine 3Surveys and Questionnaires 3Proflavine 3Positron-Emission Tomography 3Metformin 3Cisplatin 3Bevacizumab 3fludarabine phosphate 2durvalumab 2atezolizumab 2Varenicline 2Topotecan 2Taxes 2Specimen Handling 2Rituximab 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Letrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Terminated × Dexamethasone × Clear all
NCT01537861 2015-01-26

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Washington University School of Medicine

Phase EARLY_PHASE1 Terminated
7 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡